Incentives

CC4CARB solicitation is out (16 Mar 2020 deadline) / Superb WSJ podcast on antibiotic economics

Dear All, I wrote on 3 Jan 2020 (link) about the NIAID contract intended to establish an innovative Chemistry Center for Combating Antibiotic-Resistant Bacteria (CC4CARB). The formal solicitation has now gone live and can be found here. The deadline for applications is 16 Mar 2020. Get to it! In parallel, there is a superb Wall Street Journal podcast dated 13 Jan 2020 about

Read More »

Japan’s antibacterial R&D landscape / Japan calls for Pull incentives

Dear All: Late last year, I had the opportunity to hear a presentation on antibiotic R&D in Japan by Norio Ohmagari. Based in Tokyo at the National Center for Global Health and Medicine Hospital (link), Norio is Director of its (i) AMR Clinical Reference Center, (ii) Disease Control and Prevention Center, and (iii)  WHO Collaborating

Read More »

Extended deadline: NIAID call for proposals for therapeutics & vaccines for resistant bacteria

Also note several new webinars in the forward meeting list! Dear All: NIAID currently has an open BAA (Broad Agency Announcement, HHS-NIH-NIAID-BAA2019-1, link), that calls for proposals across three research areas: Medical Countermeasures (MCMs), therapeutics for resistant bacteria, and vaccines for resistant bacteria. The deadline for Research Area 001 (MCMs) is still 20 May 2019, but the

Read More »

Go, BARDA! / Outstanding Op-Ed in Forbes by Rick Bright

Dear All: Rick Bright, Director of BARDA, posted an outstanding commentary (link) in Forbes on 10 May 2019 on the Achaogen story (for more background, see my prior Scary/Scarier/Scariest blogs #1 and #2). Here are three excerpts from his commentary: “Since 2010, the Biomedical Advanced Research and Development Authority (BARDA) has been a leader in the fight against

Read More »

Start your engines! BARDA antibiotic procurement RFP / CARB-X 2019 funding round webinar

Dear All: Two things of note this afternoon… First, the previously noted BARDA RFP to acquire biothreat antibiotics is now posted here with submissions accepted through 21 June 2019: “Under this RFP, BARDA plans to support the procurement of antibiotic(s), which will either be delivered to the ASPR/SNS or maintained as VMI, using Project BioShield (PBS) funds. “PBS funds will also support

Read More »

CARB-X 2019: Calls announced covering non-traditionals, vaccines-biologics, diagnostics, and direct-acting small molecules

​Aside: There is now an application link for the Mar 2020 Antibacterial R&D GRC meeting. See calendar listing below my signature! Dear All: CARB-X this week announced its 2019 calls for proposals (link). There are four application rounds: Non-traditional approaches: Funding Round 1 will be open for Expressions of Interest June 3 – June 10, 2019, 5 PM

Read More »

Your vote counts! Support the UN proposal for an AMR-focused Sustainable Development Goal (SDG) Indicator

Dear All, Your vote counts! The UN’s Inter-Agency and Expert Group on Sustainable Development Goal Indicators (IAEG-SDGs) is conducting an open consultation on proposals it is considering including in the 2020 Comprehensive Review and is seeking the global community’s comments on these proposals (link to summary web page). The 17 SDGs were adopted in 2015 and are really driving

Read More »

New mechanisms for antibiotic reimbursement in the United States: CMS’s IPPS FY2020 Final Rule

Dear All (and with thanks to Kevin Outterson for substantial help with this newsletter), On August 2, 2019, the US government agency that administrates Medicare & Medicaid (CMS) announced several significant changes to hospital antibiotic reimbursement in US hospitals, effective October 1, 2019 (link to the very detailed Federal Register notice; go here for user-friendly summaries in Health

Read More »

The UK jumps in with a subscription model for antibiotics!

Dear All: We had hints back in January that this was coming (see this post), but now it is really happening! In brief, UK’s NHS will test the world’s first subscription-style payment model in which payments delinked from volume are used to incentivise pharmaceutical companies to develop new drugs for resistant infections. Below my signature, I’ve

Read More »
Scroll to Top